LYON, France, September 26, 2023 Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
EQS-News: France Biotech / Key word(s): Conference The 4th edition of the HealthTech Innovation Days (HTID), in Paris, succeeded in bringing together key players of the European healthtech